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Abstract 
Cold agglutinin disease (CAD) is an autoimmune hemolytic anemia (AIHA) generally 
caused by IgM autoantibodies which exhibit maximal reactivity at 4°C. CAD can be 
idiopathic or secondary to some diseases and/or conditions. Only a minority of cases of 
secondary AIHA in non-Hodgkin’s lymphoma (NHL) are associated with cold antibodies. 
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of NHLs with a 
proportion of nearly 30% of all adult cases. 40% of patients with DLBCL have an 
extranodal disease or at least disease initially confined to extranodal sites. The most 
common extranodal site is the gastrointestinal tract. We present a patient with primary 
gastrointestinal DLBCL who presented with CAD and was treated with a CHOP-Rituximab 
regimen. 
Introduction 
Autoimmune hemolytic anemia (AIHA) is a term used for anemias caused by 
destruction of erythrocytes by antibodies that are directed against membrane antigens of 
the patients’ red blood cells (RBCs). Among all kinds of anemias, AIHA is an uncommon 
form. Even among the groups of hemolytic anemias, AIHA is not the most common 
variant and no more than 5–10 patients with AIHA per year are diagnosed [1]. The 
majority of AIHA cases are mediated by warm-reactive autoantibodies, i.e. antibodies 
displaying optimal reactivity with human RBCs at 37°C and which are usually of the IgG 
immunoglobulin class. In contrast, cold agglutinin disease (CAD) is generally caused by 
IgM autoantibodies which exhibit maximal reactivity at 4°C. CAD can be idiopathic or Case Rep Gastroenterol 2011;5:262–266 
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secondary to some diseases and/or conditions (e.g. Mycoplasma pneumoniae infection, 
infectious mononucleosis, other viral infections or malignant diseases such as 
lymphoproliferative disorders). Only a minority of cases of secondary AIHA in 
non-Hodgkin’s lymphoma (NHL) are associated with cold antibodies. In a cohort of 
370 patients with NHL, 1.1% had cold reacting antibodies [2]. Diffuse large B cell 
lymphoma (DLBCL) is the most common subtype of NHLs with a proportion of nearly 
25–30% of all adult cases [3]. 40% of patients with DLBCL have extranodal disease or at 
least disease initially confined to extranodal sites [4]. The most common extranodal site is 
the gastrointestinal tract. We present a patient with primary gastrointestinal DLBCL who 
presented with CAD. 
Case Report 
A 46-year-old otherwise healthy female patient was admitted to the outpatient clinic of our 
hematology department with fatigue and anemia in November 2010. Before that she saw another 
physician and her hemoglobin (Hb) level was found to be 9.8 g/dl; a diagnosis of iron deficiency anemia 
was made and she was put on oral iron replacement therapy. Since her complaints did not resolve and 
her Hb level decreased to 4.8 g/dl, she was admitted to our institution. Physical examination revealed 
paleness in the mucous membranes and subicterus; no peripheral lymphadenopathy or organomegaly 
was detected. The interesting thing about her complete blood count was that her hematocrit (Hct) was 
discordant with her Hb level (Hb: 4.8 g/dl; Hct: 9%) and she had a high mean corpuscular volume of 
115.7 fl, mean cell Hb of 64.3 pg and mean cell Hb concentration of 55.6 g/dl with automated counter. 
White blood cell and platelet counts were normal. Agglutination was seen in anticoagulated blood at 
room temperature and disappeared upon warming the blood to 37°C; repeating the complete blood 
count after warming the blood avoided this problem. Peripheral blood smear revealed RBC clumps. Her 
reticulocyte was as high as 16% and direct antibody (Coombs) test was positive, so AIHA and CAD was 
thought to be the diagnosis. Cold agglutinin test was found to be positive with a titer of 1/2,560 and 
cryoglobulinemia was excluded. In her blood chemistry lactate dehydrogenase was 520 U/l (normal 
125–243), indirect bilirubin was 2.76 mg/dl and haptoglobin level was low. Serum protein 
electrophoresis and serum immunoglobulin levels were normal.  
80 mg/day methylprednisolone with folic acid replacement therapy was initiated. Epstein-Barr virus, 
cytomegalovirus, herpes simplex virus, hepatitis B and C viruses as well as human immunodeficiency 
virus were serologically negative and serology for Mycoplasma pneumoniae was also found to be 
negative. She had no signs of arthritis, Raynaud phenomenon or any other rheumatological diseases. 
Thoracic and abdominal computed tomography (CT) was done in order to exclude lymphoproliferative 
disorders. Thoracic CT was normal whereas abdominal CT revealed increased wall thickness in a 
segment of the terminal ileum. There were also mesenteric and paraaortic lymphadenopathies 20 mm in 
diameter. A colonoscopy was performed, a mass in the lumen of terminal ileum was detected and a 
biopsy was taken (fig. 1). Histopathological evaluation of the biopsy specimen was consistent with 
DLBCL. Positron emission tomography-computed tomography (PET-CT) showed an increased uptake 
of F-18 fluorodeoxyglucose (FDG) in the terminal ileum (fig. 2). Bone marrow infiltration was detected 
and there were no complaints of B symptoms, so the patient was staged as IVAE disease with an 
international prognostic index score of 2. CHOP (cyclophosphamide 750 mg/m
2/day D1, Adriamycin 
50 mg/m
2/day D1, vincristine 2 mg/day D1 and methylprednisolone 80 mg/day D1–5) chemotherapy with 
Rituximab 375 mg/m
2/day D1 (R-CHOP) was initiated. After administering the chemotherapy, her Hb 
and Hct levels gradually increased and the hemolysis resolved in the following days; after the second 
course of R-CHOP she was discharged from the hospital. 
Discussion 
AIHA may be associated with either IgG antibodies which react with the RBC surface 
at warm temperature or with (usually) IgM antibodies which react below body 
temperature. The latter are therefore named ‘cold agglutinins’. Cold agglutinins are IgM Case Rep Gastroenterol 2011;5:262–266 
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antibodies reacting with untreated adult red cells (anti-I) or reacting with fetal or cord red 
cells (anti-i). CAD accounts for 13–15% of cases of AIHA [5]. CAD can be primary or 
cold agglutinins are produced either in response to infection or secondary to neoplastic 
growth of a single B cell clone. Economopoulos et al. reviewed 370 patients with NHL and 
found that 23 (6.2%) had AIHA, 4 of whom (1.1%) had cold reacting antibodies [2]. 
Sallah et al. published characteristics of 16 patients with NHL and AIHA out of a cohort 
of 501 patients, of whom 3 had CAD and only 1 had a diagnosis of DLBCL [6]. 25 patients 
with high-grade NHL and AIHA were demonstrated in the literature, 22 of them had 
DLBCL [7]. Berentsen et al. found 76% of patients with chronic CAD to have underlying 
lymphoma and most of the cases were lymphoplasmacytic lymphoma, marginal zone 
lymphoma and small lymphocytic lymphoma/chronic lymphocytic leukemia [8]. About 
3.5% of patients with CAD and indolent NHL progressed to DLBCL within a median 
observation time of 5 years. This was not the scenario in our patient because she did not 
have a diagnosis of low-grade lymphoma before the diagnosis of DLBCL was made. 
DLBCL presenting with CAD is a rare entity. The association of CAD with extranodal 
presentations of NHL has been characterized [8]. Airaghi et al. published a patient with 
DLBCL with adrenal and renal involvement and CAD [9]. Another DLBCL patient with 
gastrointestinal involvement and CAD was published in the literature before [10], but he 
had extensive disease with gastrointestinal involvement and bone marrow infiltration 
with hemophagocytic syndrome and polyneuropathy, and the diagnosis was made 
postmortem. Our patient also had gastrointestinal involvement and bone marrow 
infiltration, but neither hemophagocytosis nor polyneuropathy was detected. Níáinle et al. 
published a DLBCL patient with nodal disease, bone marrow involvement and CAD [11], 
and a DLBCL case with isolated bone marrow involvement and cold agglutinins was 
described before [12]. Our patient had no nodal disease, only a mass in the terminal 
ileum, and although lymph nodes were detected by abdominal CT, they did not show 
FDG uptake on PET-CT. Since in secondary CAD the underlying disease should be 
promptly treated, we started R-CHOP in order to overwhelm the clinical picture. 
In conclusion, CAD accounts for 15% of cases of AIHA and most of the cases are 
chronic lymphocytic leukemia and lymphoma (most commonly low-grade NHLs). The 
association between CAD and DLBCL is rare, extranodal DLBCL with cold agglutinins is 
even rarer. Here we present a case of DLBCL with gastrointestinal and bone marrow 
involvement and CAD. To our knowledge, our case is the only reported case of CAD in a 
patient with primary gastrointestinal involvement of DLBCL. 
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Fig. 1. Colonoscopy was performed and a mass in the lumen of the terminal ileum was detected. 
 
 
 
Fig. 2. PET-CT showed an increased FDG uptake in the terminal ileum. 
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